High Fidelity Drug Discovery
– Get an early lead
DNA encoded library screening in living cells
DELs in Cells – Unique offering by Vipergen
High success rate and low attrition rate – screening is performed under physiologically relevant conditionsBroad target space and short TAT – no need for purified target protein!
News
Press release
Lund, Sweden and Copenhagen, Denmark – November 11, 2024
SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership with the goal to offer enhanced hit and lead identification services based on their complementary technology platforms.
By combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, the companies will enhance their drug discovery services by offering expedited hit identification and lead generation.
Vipergen releases DELs in Cells – Snap
DELs in Cells – Snap, provides an easy, fast, and affordable way to get an early lead.
You provide the amino acid sequence of your target protein, and we perform test for successful expression followed by DEL screening in a living cell.
Never been easier – low cost – standardized process – high success rate – no purified target protein needed.
Vipergen releases DELs in Cells – PPI inhibitor Direct
Vipergen introduces DELs in Cells – PPI inhibitor Direct, a novel service that offers a method for directly discovering protein-protein interaction inhibitors for your target proteins.
With this service, you provide the amino acid sequence of the target proteins of interest (POIs), and we screen in living cells, using our unique multiplexing technology to directly discover PPI inhibitors.
Vipergen releases DELs in Cells – Molecular Glue Direct
Vipergen introduces DELs in Cells – Molecular Glue Direct, a novel service that offers a method for directly discovering molecular glues for your target protein.
With this service, you provide the amino acid sequence of the target protein of interest (POI), and we screen in living cells, using our unique multiplexing technology to directly discover molecular glues.
Press release
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.
Meet us at
Drug Discovery Chemistry
Barcelona, Spain, December 2-3, 2024.
Vipergen will show a poster entitled:
DELs in Cells: Direct Screening of DNA Encoded Libraries for PPI Inhibitors.
17th Winter Conference on Medicinal & Bioorganic Chemistry
Steamboat Springs, Colorado, US, February 2-6, 2025.
Vipergen will show a poster entitled:
DELs in Cells – Direct Screening for PPI Inhibitors.
World-leading provider of small molecule drug discovery services based on DNA-encoded library technologies
Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies.
Vipergen is offering different business models, including simple Fee-For-Service.
Do you have an inquiry?
Improve the starting point for lead optimization with Vipergen’s cutting-edge technologies.
Experience our unique approach to challenging targets. Ready to transform your research? Contact us today and explore partnership opportunities.
What we do
Vipergen revolutionizes drug discovery by screening for novel molecules directly in living cells, providing the tool to target complex molecular entities, improve hit rates, and develop effective pharmaceuticals.
Our approach prioritizes physiological relevance, ensuring a higher success rate and lower attrition rates in drug development.
We excel in finding the right molecular keys for a variety of complex biological locks.
How we do it
Our advanced technology allows us to conduct screenings in living cells, increasing the target space and reducing turnaround time significantly.
Unlike traditional methods, our process does not require a purified version of the target protein, enabling us to handle even the most challenging targets with ease and to initiate screenings more rapidly.
Who we are
Vipergen stands as a pioneer in the biotech and pharmaceutical industry, driven by a commitment to innovation and excellence.
Our team of highly qualified professionals brings together extensive expertise in chemistry and biology.
We are recognized for our unique ability to address complex drug discovery challenges that are beyond the reach of conventional approaches.
Cellular Binder Trap Enrichment (cBTE)
● 3rd generation screening technology
● Screening inside a living cell (unique capability)
● Physiologically relevant conditions
● Lower attrition rate
● No need for purified target protein (unique capability)
● Broader protein target space
● Multiplexing (unique capability)
Binder Trap Enrichment (BTE)
● 2nd generation screening technology
● Solution based (homogenous assay)
● No matrix binders
● No target denaturation by immobilization
● Low false positive rate
● Multiplexing (unique capability)
YoctoReactor (yR)
● 2nd generation library synthesis technology
● Chemical diversity by building blocks
● Physicochemical properties kept in check
● 100% match between code and compound
● Purification after each synthesis step (unique capability)
● Low false positive rate
